Stock listing
Shenzhen:300199 Hybio Pharmaceutical Co., Ltd. (翰宇药业) 股价
Follow Hybio Pharmaceutical Co., Ltd. into a list and get an email when it puts out news.
Share price · SZSE:300199
¥19.59 CNY -1.90 (-8.8%)
Close on Nov 20, 2026
- Day range
- ¥19.59 – ¥20.68 CNYNov 20, 2026
- Volume
- 27.32M sharesNov 20, 2026
- Market cap
- ¥17.30B CNYAt the close on Nov 20, 2026 · price × 883.2M shares outstanding
- 52-week range
- ¥16.23 – ¥27.70 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ¥1.06B CNYMedian day 39.02M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SZSE:300199 · CNY, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ¥19.59 | -1.90 | -8.8% | ¥20.60 | ¥20.68 | ¥19.59 | 27,316,237 | |
| ¥21.49 | -0.71 | -3.2% | ¥22.36 | ¥22.43 | ¥21.00 | 30,200,110 | |
| ¥22.20 | +0.17 | +0.8% | ¥21.86 | ¥22.56 | ¥21.70 | 25,079,498 | |
| ¥22.03 | -0.76 | -3.3% | ¥22.42 | ¥22.78 | ¥21.89 | 27,147,689 | |
| ¥22.79 | -0.26 | -1.1% | ¥23.15 | ¥23.85 | ¥22.70 | 38,240,511 | |
| ¥23.05 | -0.47 | -2.0% | ¥23.40 | ¥23.91 | ¥23.03 | 32,142,235 | |
| ¥23.52 | -0.08 | -0.3% | ¥23.42 | ¥23.62 | ¥22.92 | 31,487,348 | |
| ¥23.60 | +0.05 | +0.2% | ¥24.01 | ¥24.17 | ¥23.30 | 28,630,338 | |
| ¥23.55 | -0.59 | -2.4% | ¥24.60 | ¥24.83 | ¥23.54 | 34,239,730 | |
| ¥24.14 | -0.73 | -2.9% | ¥24.10 | ¥24.85 | ¥23.97 | 50,425,233 | |
| ¥24.87 | +2.16 | +9.5% | ¥22.71 | ¥25.27 | ¥22.71 | 68,921,862 | |
| ¥22.71 | +1.50 | +7.1% | ¥21.09 | ¥22.88 | ¥21.02 | 45,806,354 | |
| ¥21.21 | -0.88 | -4.0% | ¥21.87 | ¥22.20 | ¥21.20 | 32,039,060 | |
| ¥22.09 | +0.23 | +1.1% | ¥21.74 | ¥22.35 | ¥21.35 | 28,573,650 | |
| ¥21.86 | -0.45 | -2.0% | ¥22.52 | ¥23.25 | ¥21.02 | 40,645,702 | |
| ¥22.31 | -0.85 | -3.7% | ¥22.99 | ¥23.20 | ¥22.23 | 33,171,321 | |
| ¥23.16 | -0.04 | -0.2% | ¥23.20 | ¥23.68 | ¥22.87 | 34,957,035 | |
| ¥23.20 | -1.24 | -5.1% | ¥24.95 | ¥25.15 | ¥23.20 | 49,047,688 | |
| ¥24.44 | -1.36 | -5.3% | ¥25.35 | ¥25.48 | ¥24.39 | 45,912,124 | |
| ¥25.80 | +1.16 | +4.7% | ¥24.34 | ¥25.96 | ¥24.02 | 56,935,914 | |
| ¥24.64 | -2.07 | -7.7% | ¥26.50 | ¥26.75 | ¥24.61 | 66,329,671 | |
| ¥26.71 | +0.21 | +0.8% | ¥26.83 | ¥27.70 | ¥26.62 | 69,938,638 | |
| ¥26.50 | +0.20 | +0.8% | ¥25.83 | ¥26.78 | ¥25.56 | 58,709,109 | |
| ¥26.30 | +1.37 | +5.5% | ¥24.85 | ¥26.50 | ¥24.48 | 78,983,047 | |
| ¥24.93 | +0.38 | +1.5% | ¥25.01 | ¥26.37 | ¥24.64 | 70,831,043 | |
| ¥24.55 | -0.33 | -1.3% | ¥24.56 | ¥25.67 | ¥24.43 | 62,294,129 | |
| ¥24.88 | -0.67 | -2.6% | ¥24.99 | ¥25.69 | ¥24.63 | 63,345,035 | |
| ¥25.55 | +0.66 | +2.7% | ¥25.18 | ¥26.38 | ¥24.98 | 103,980,414 | |
| ¥24.89 | +1.18 | +5.0% | ¥23.60 | ¥25.15 | ¥23.01 | 71,768,109 | |
| ¥23.71 | -0.04 | -0.2% | ¥23.52 | ¥23.84 | ¥22.74 | 41,550,457 | |
| ¥23.75 | -0.17 | -0.7% | ¥24.16 | ¥24.29 | ¥23.36 | 53,998,613 | |
| ¥23.92 | +1.13 | +5.0% | ¥22.70 | ¥24.93 | ¥22.70 | 77,790,086 | |
| ¥22.79 | +0.39 | +1.7% | ¥22.28 | ¥23.04 | ¥22.06 | 28,227,367 | |
| ¥22.40 | -0.90 | -3.9% | ¥23.13 | ¥23.42 | ¥22.31 | 34,804,828 | |
| ¥23.30 | -0.99 | -4.1% | ¥24.15 | ¥24.25 | ¥23.23 | 43,955,848 | |
| ¥24.29 | +0.44 | +1.8% | ¥24.10 | ¥24.44 | ¥23.70 | 49,657,566 | |
| ¥23.85 | +0.26 | +1.1% | ¥23.26 | ¥24.18 | ¥22.90 | 53,689,184 | |
| ¥23.59 | +0.09 | +0.4% | ¥23.50 | ¥24.09 | ¥23.33 | 47,095,832 | |
| ¥23.50 | -0.15 | -0.6% | ¥23.87 | ¥24.19 | ¥23.32 | 39,092,480 | |
| ¥23.65 | +0.12 | +0.5% | ¥23.40 | ¥24.19 | ¥23.32 | 35,203,266 | |
| ¥23.53 | -0.06 | -0.3% | ¥23.59 | ¥23.75 | ¥23.03 | 34,157,801 | |
| ¥23.59 | +0.08 | +0.3% | ¥23.55 | ¥23.94 | ¥23.16 | 29,548,527 | |
| ¥23.51 | +0.74 | +3.2% | ¥22.70 | ¥23.63 | ¥22.52 | 36,898,094 | |
| ¥22.77 | -0.48 | -2.1% | ¥23.25 | ¥23.27 | ¥22.26 | 30,902,922 | |
| ¥23.25 | +0.09 | +0.4% | ¥23.12 | ¥23.56 | ¥22.65 | 30,731,164 | |
| ¥23.16 | +0.28 | +1.2% | ¥22.59 | ¥23.78 | ¥22.49 | 39,710,660 | |
| ¥22.88 | -0.55 | -2.3% | ¥23.51 | ¥23.58 | ¥22.81 | 33,685,605 | |
| ¥23.43 | +0.61 | +2.7% | ¥22.80 | ¥23.55 | ¥22.65 | 38,947,895 | |
| ¥22.82 | -0.02 | -0.1% | ¥23.10 | ¥23.27 | ¥22.60 | 37,394,715 | |
| ¥22.84 | -0.01 | 0.0% | ¥22.97 | ¥23.30 | ¥22.51 | 31,054,096 | |
| ¥22.85 | -0.10 | -0.4% | ¥22.95 | ¥23.00 | ¥22.39 | 24,224,355 | |
| ¥22.95 | -0.01 | 0.0% | ¥23.00 | ¥23.08 | ¥22.63 | 25,121,035 | |
| ¥22.96 | -0.49 | -2.1% | ¥23.08 | ¥24.04 | ¥22.77 | 38,742,910 | |
| ¥23.45 | +0.11 | +0.5% | ¥23.33 | ¥24.02 | ¥23.09 | 37,388,695 | |
| ¥23.34 | +0.67 | +3.0% | ¥22.71 | ¥23.45 | ¥22.41 | 33,817,426 | |
| ¥22.67 | -0.81 | -3.4% | ¥23.32 | ¥23.50 | ¥22.57 | 40,592,578 | |
| ¥23.48 | +1.31 | +5.9% | ¥22.09 | ¥23.70 | ¥21.71 | 58,949,246 | |
| ¥22.17 | -0.93 | -4.0% | ¥23.11 | ¥23.21 | ¥21.70 | 47,457,625 | |
| ¥23.10 | -1.00 | -4.1% | ¥24.00 | ¥24.08 | ¥22.95 | 50,297,199 | |
| ¥24.10 | +0.30 | +1.3% | ¥24.51 | ¥25.13 | ¥23.88 | 62,392,488 |
Splits
3 splits since 2012 · SZSE:300199 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 2-for-1 | Split | |
| 2-for-1 | Split | |
| 2-for-1 | Split |
- Ticker
- Shenzhen:300199
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Shenzhen
- Currency
- CNY
What changed lately
Latest news release · Jul 6, 2026
Hybio Pharmaceutical Unit's Chemical API Liraglutide Approved By China's Regulator
Latest news
Hybio Pharmaceutical Unit's Chemical API Liraglutide Approved By China's Regulator
Jul 6, 2026
Closed ¥24.70 (-4.3%) on Jul 7, 2026
Hybio Pharmaceutical's Liraglutide Injection Approved By China's National Medical Products Administration
Jul 1, 2026
Closed ¥23.10 (-3.5%) on Jul 2, 2026
Hybio's generic weight-loss drug set for FDA review
Jun 30, 2026
Closed ¥23.93 (+8.4%) on Jul 1, 2026
Hybio Pharmaceutical Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 3 in the last 12 months · 4 in all · newest Jul 6, 2026 · oldest 2025
Valuation
P/E 43.1× against a median of 18.5×: 9th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- ¥18.03B CNY
- P/E
- 43.1×
- EV/sales
- 11.8×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 16.1×
- Gross margin
- 62.9%
- Operating margin
- 35.2%
- Net margin
- 26.3%
- Debt to equity
- 0.9×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Hybio Pharmaceutical Co., Ltd. Class A · SZSE:300199 | US$2.60B | US$2.71B | 43.1× | 11.8× | n/a | 16.1× | 26.3% | 0.9× | n/a |
| China Medical System Holdings Ltd. · HKEX:867 | US$2.87B | US$2.13B | 12.8× | 1.7× | 7.7× | 1.1× | 18.1% | 0.1× | n/a |
| Joincare Pharmaceutical Group Industry Co., Ltd. Class A · SSE:600380 | US$2.80B | US$1.16B | 16.5× | 0.6× | n/a | 1.3× | 8.4% | 0.1× | n/a |
| Livzon Pharmaceutical Group, Inc. Class A · SZSE:000513 | US$2.72B | US$1.65B | 11.7× | 1.1× | n/a | 1.4× | 15.2% | 0.0× | n/a |
| Bavarian Nordic A/S · OMXCOP:BAVA | US$2.70B | US$2.38B | 20.5× | 2.6× | 8.6× | 1.4× | 14.2% | 0.0× | n/a |
| Betta Pharmaceuticals Co., Ltd. Class A · SZSE:300558 | US$2.64B | US$2.72B | 66.1× | 4.8× | n/a | 2.7× | 7.0% | 0.2× | n/a |
| Hanmi Science Co., Ltd · KRX:008930 | US$2.60B | US$2.53B | 23.2× | 2.5× | 57.2× | 3.3× | 10.8% | 0.0× | n/a |
| Hypera S.A. · BMFBOVESPA:HYPE3 | US$2.59B | US$3.57B | 8.5× | 2.3× | 7.4× | 1.0× | 20.1% | 0.5× | n/a |
| Kangmei Pharmaceutical Co., Ltd Class A · SSE:600518 | US$2.57B | US$2.37B | 189× | 3.3× | n/a | 2.3× | 1.9% | 0.0× | n/a |
| Granules India Limited · NSE:GRANULES | US$2.42B | US$2.32B | 31.4× | 3.6× | 16.1× | 3.4× | 12.1% | 0.2× | n/a |
| Prestige Consumer Healthcare Inc. · NYSE:PBH | US$2.35B | US$4.39B | 15.2× | 3.8× | 13.4× | 1.2× | 13.3% | 1.1× | 0.34 |
| Median of the others | US$2.62B | US$2.37B | 18.5× | 2.5× | 11.0× | 1.4× | 12.7% | 0.1× | 0.34 |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2025 | Oct 29, 2025 | −6.3% |
| Q2 2025 | Aug 22, 2025 | −3.3% |
| Q1 2025 | Apr 25, 2025 · Before open | −0.3% |
| Q3 2024 | Oct 29, 2024 · Before open | −2.3% |
| Q2 2024 | Aug 24, 2024 | +1.3% |
| Q1 2024 | Apr 26, 2024 · After close | +0.6% |
| Q3 2023 | Oct 30, 2023 | −2.2% |
| Q2 2023 | Aug 15, 2023 | −5.1% |
| Q1 2023 | Apr 27, 2023 | +7.4% |
| Q3 2022 | Oct 29, 2022 | +4.2% |
All 15 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2022 | Aug 27, 2022 | +0.5% |
| Q1 2022 | Apr 28, 2022 · Before open | +1.1% |
| Quarter to Sep 30, 2021 | Oct 29, 2021 | +7.2% |
| Quarter to Jun 30, 2021 | Aug 28, 2021 | −2.1% |
| Quarter to Mar 31, 2021 | Apr 28, 2021 · Before open | +0.6% |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 966.4M | 590.2M | 431.4M | 704.3M | 736.0M | 721.7M | 614.2M | 1.26B | 1.25B | 855.0M |
| Cost of revenue | 402.4M | 281.5M | 260.4M | 194.8M | 271.9M | 153.5M | 133.9M | 184.3M | 197.0M | 169.8M |
| Gross profit | 564.0M | 308.7M | 171.0M | 509.5M | 464.1M | 568.2M | 480.3M | 1.08B | 1.05B | 685.2M |
| Research and development | 126.9M | 88.0M | 161.5M | 158.7M | 105.7M | 143.9M | 180.3M | 94.9M | 89.4M | 60.4M |
| Selling, general and administrative | 117.4M | 119.5M | 121.1M | 101.7M | 100.3M | 69.7M | 162.2M | 151.2M | 113.5M | 129.6M |
| Operating income | 218.5M | -161.4M | -507.5M | -370.8M | 39.1M | -574.4M | -905.3M | -320.3M | 354.4M | 277.9M |
| Depreciation and amortization | 132.7M | 148.3M | 154.9M | 144.5M | 135.8M | 108.7M | 105.5M | 100.9M | 100.4M | 90.9M |
| EBITDA | 351.3M | -13.1M | -352.6M | -226.3M | 174.9M | -465.7M | -799.8M | -219.5M | 454.8M | 368.8M |
| Interest expense | 98.0M | 117.9M | 125.8M | 109.7M | 99.7M | 65.3M | 94.5M | 48.4M | 25.9M | 40.7M |
| Income before tax | 64.2M | -162.4M | -511.1M | -372.8M | 33.7M | -588.2M | -891.3M | -333.7M | 350.5M | 309.2M |
| Income tax | 17.7M | 4.34M | -265.0K | 5.24M | 21.1M | -6.53M | 7.05M | 20.8M | 17.3M | |
| Net income | 36.6M | -173.7M | -513.9M | -370.6M | 30.8M | -609.4M | -884.8M | -340.8M | 329.7M | 291.9M |
| Earnings per share, basic | 0.04 | -0.20 | -0.58 | -0.42 | 0.03 | -0.69 | -1.00 | -0.37 | 0.35 | 0.33 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 100.7M | 94.9M | 344.0M | 106.3M | 138.9M | 451.6M | 820.8M | 1.56B | 1.27B | 880.5M |
| Short-term investments | 1.23M | 1.11M | 160.6M | 477.7M | ||||||
| Receivables | 121.6M | 104.9M | 152.1M | 329.9M | 334.5M | 355.1M | 847.3M | 1.25B | 1.17B | 813.8M |
| Inventory | 261.4M | 238.6M | 152.6M | 190.0M | 157.1M | 186.8M | 152.0M | 161.6M | 142.8M | 136.6M |
| Current assets | 523.6M | 463.0M | 683.6M | 812.3M | 1.16B | 1.05B | 1.89B | 3.02B | 2.60B | 1.84B |
| Property, plant and equipment | 1.94B | 1.99B | 1.98B | 1.79B | 1.33B | 1.06B | 965.1M | |||
| Goodwill | 191.1K | 343.6M | 872.4M | 898.6M | ||||||
| Total assets | 3.15B | 3.01B | 3.28B | 3.61B | 3.91B | 4.04B | 4.72B | 5.66B | 5.30B | 4.46B |
| Accounts payable | 262.0M | 218.3M | 108.5M | 129.1M | 90.7M | 125.5M | 130.1M | 74.4M | 49.1M | 53.1M |
| Current liabilities | 1.78B | 1.42B | 1.42B | 1.15B | 743.8M | 1.11B | 1.14B | 831.9M | 865.0M | 330.9M |
| Long-term debt | 623.4M | 861.1M | 938.6M | 1.02B | 1.37B | 1.14B | 1.27B | 1.35B | 458.5M | 421.2M |
| Total debt | 1.50B | 1.56B | 1.34B | 1.71B | 1.74B | 1.91B | 1.76B | 774.8M | 417.7M | |
| Total liabilities | 2.52B | 2.41B | 2.49B | 2.31B | 2.26B | 2.36B | 2.49B | 2.27B | 1.41B | 852.4M |
| Shareholders' equity | 614.0M | 578.6M | 758.8M | 1.27B | 1.58B | 1.64B | 2.23B | 3.39B | 3.88B | 3.60B |
| Shares outstanding | 883.2M | 868.3M | 886.0M | 883.2M | 883.2M | 883.2M | 883.2M | 921.0M | 942.1M | 884.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 233.9M | 164.7M | -3.54M | 15.8M | 156.8M | 48.0M | 104.6M | 47.0M | 228.6M | 296.4M |
| Capital spending | -234.4M | -115.8M | -81.8M | -189.8M | -199.0M | -243.7M | -570.2M | -365.6M | -221.1M | -116.1M |
| Free cash flow | -449.8K | 48.9M | -85.3M | -174.0M | -42.2M | -195.7M | -465.5M | -318.6M | -7.39M | 180.4M |
| Cash from investing | -70.0M | 147.7M | 51.7M | -178.4M | -258.5M | -596.0M | -419.9M | -223.5M | -131.0M | |
| Cash from financing | -345.5M | 95.8M | -71.1M | -253.7M | -71.7M | -425.2M | 654.6M | 393.2M | 524.4M | |
| Dividends paid | -94.8M | -111.7M | -117.9M | -114.8M | -115.6M | -105.0M | -114.6M | -252.8M | -128.3M | -63.1M |
| Share buybacks | -413.2M | -105.9M | ||||||||
| Change in cash | -15.3M | -247.4M | 240.9M | -1.51M | -276.8M | -280.2M | -906.7M | 295.8M | 387.9M | 694.8M |
Cap table
Built by 6ix from Hybio Pharmaceutical Co., Ltd. Class A’s releases
- Common shares
- 883,241,336
- Fully diluted
- 883,241,336
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 883,241,336 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 883,241,336 |
Log in to ask 6ix AI your own questions about Hybio Pharmaceutical Co., Ltd.